Clinical Study
Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations
Table 4
Preliminary cost-effectiveness estimates. Cost-effectiveness estimates for BSC and six established therapies (6ā9) for widespread mCRC are noted in conjunction with liberal estimates of cost for MCA. Our proposed adjunctive cost-effectiveness ratio, or ACER, was used to calculate the estimated cost of MCA when paired with systemic regimens.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumes 1.9 cryoablation procedures per patient and more image intensive followup. A conversion factor of 1.67 from pounds to dollars was used to allow easier comparison and conforms to the difference between established definitions of cost efficacy of $100,000 [28]. ACER: adjunctive role for, MCA: assumes costs are additive and divided by a total LYG of 1.97 for MCA. MCA: multisite cryoablation. 5-FU: 5-fluorouracil. LV: leucovorin. FOLFOX: 5-FU, leucovorin, and oxaliplatin. FOLFIRI: 5-FU, leucovorin, and irinotecan. BV: bevacizumab. IR: irinotecan. CX: cetuximab. |